PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of gutGutVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
Gut. 2007 November; 56(11): 1493–1494.
PMCID: PMC2095675

Obesity and the rising incidence of oesophageal and gastric adenocarcinoma: what is the link?

Short abstract

While data support an association between BMI and oesophageal adenocarcinoma, it is not known why the cancer incidence differs so markedly by gender and ethnicity

The incidence of oesophageal adenocarcinoma has increased over 500% in some countries during the last three decades, but the reasons for this rise are unclear.1 The most intractable problem to date has been explaining why the rates for oesophageal adenocarcinoma vary substantially by race (more common in Caucasians), gender (more common in men), and geography.1,2,3,4,5,6 The increasing prevalence of obesity in society may provide a partial explanation for the increases in incidence. The article by Merry et al. in this issue of Gut describes a well‐designed cohort study which evaluates whether measures of body size, such as height and the body mass index (BMI), are associated with the subsequent risk of oesophageal and gastric cardia adenocarcinomas (see page 1503).7 Its strengths include its cohort design, high‐quality data, the ability to evaluate BMI early in adult life (when carcinogenic processes such as Barrett's oesophagus may begin) and with weight gain, the completeness of cancer follow‐up, the large size (which permitted stratification by gender), and its evaluation of different cancer types within a single population. The study adds knowledge particularly in two areas. First, it found that a high baseline adult BMI and increases in BMI after the age of 20, but not BMI at age 20, were strongly associated with oesophageal adenocarcinoma and cardia adenocarcinoma; this suggests that interventions aimed at preventing weight gain in adulthood may decrease the risk of oesophageal and cardia adenocarcinomas. Second, it provided detailed evaluations of height, which demonstrate no clear association between height and oesophageal or cardia adenocarcinomas. This finding suggests it is excess body weight for any given height, rather than a peculiarity of the BMI ratio equation, that accounts for the associations between BMI and these malignancies.

Is the study by Merry et al.7 consistent with the existing literature on the associations between BMI and oesophageal adenocarcinoma? Yes. Several publications indicate that there is an association between increasing BMI and the risk of oesophageal adenocarcinoma, although the magnitude is moderate. Recent systematic reviews of the association between BMI and the risk of oesophageal adenocarcinoma identified 14 studies that evaluated the relationships between body fat and oesophageal or cardia adenocarcinomas (two cohorts and 12 case‐control studies, totalling 2488 persons with oesophageal adenocarcinoma and 2509 persons with cardia adenocarcinomas). A high BMI (>25) was associated with an increased risk of oesophageal adenocarcinoma in both men and women (men OR = 2.2; 95% CI, 1.7 to 2.7; women OR = 2.0; 95% CI, 1.4 to 2.9) and higher BMIs were associated with a higher cancer risk (overweight men OR = 1.8; 95% CI, 1.5 to 2.2 vs obese men OR = 2.4; 95% CI, 1.9 to 3.2).8,9 Thus, the current study is concordant with prior data, but it still raises the question of how BMI might increase cancer risk.

A potential causal pathway from body size to cancer may be from normal to gastro‐oesophageal reflux disease (GORD) to Barrett's oesophagus to oesophageal adenocarcinoma and some gastro‐oesophageal junction adenocarcinomas. People with Barrett's oesophagus, a metaplastic change of the oesophagus, have a 30–40‐fold increased risk of oesophageal adenocarcinoma.10 In such a direct pathway, cancer risk factors, such as BMI, could act by increasing the prevalence of GORD, by increasing the prevalence of Barrett's oesophagus among people with GORD, or by enhancing the risk of malignant transformation from Barrett's oesophagus to adenocarcinoma. Other factors (eg, smoking, diet or genetics) may also influence the steps on this pathway; for example, environmental exposures such as smoking may influence whether someone with GORD develops Barrett's oesophagus, or whether someone with Barrett's oesophagus develops cancer. However, if the main pathway starts with GORD, then decreasing the risk of reflux alone might be expected to proportionately decrease the risk of the subsequent steps in the pathway: Barrett's oesophagus and oesophageal adenocarcinoma. Therefore, knowledge of when putative risk factors act is crucial for timing potential interventions.

The first question then becomes, might BMI increase the risk of cancer simply by increasing the chance of gastro‐oesophageal reflux disease? Two recent statistical syntheses of the associations between BMI and GORD found moderate positive associations between increasing BMI and GORD in the USA, but not consistently in other countries, and some high‐quality studies showed no association.8,11 Thus, there may be a general, though not strong, relationship between BMI and GORD symptoms. The main barrier to this line of reasoning for the carcinogenic pathway is that GORD symptoms do not track strongly with cancer risk in the population as a whole. GORD is common among men and women, and in all ethnicities, but the risk of cancer is markedly higher in Caucasian men.2,12

The second question might be whether BMI increases the risk of Barrett's oesophagus, independent of GORD. In other words, among two persons with equivalent amounts of GORD, will the heavier person be more likely to develop Barrett's oesophagus?13 Several large case‐control studies that may partially address this question are under way and results from the first studies suggest that BMI alone is not a strong risk factor for Barrett's oesophagus.14

Finally, might BMI increase the risk of Barrett's oesophagus progressing to adenocarcinoma of the oesophagus or gastro‐oesophageal junction, independent of GORD? Although BMI and abdominal size may be risk factors for the malignant progression of Barrett's oesophagus, it is unclear from the existing small studies whether this is independent of GORD.15,16 A substantial barrier to research on reflux is the imperfect association between GORD symptoms and acid reflux. Persons with severe acid reflux may have few symptoms and, conversely, some with severe symptoms may have modest reflux. If this affected all groups equally, we might make some comparisons, but there are data to suggest this may not be the case. A study of employees at a US veterans hospital suggested that, for similar symptoms, African–Americans were less likely to have oesophagitis.17 It may also be that only an isolated oesophagitis from a brief vomiting illness or a toxic injury (rather than prolonged periods of reflux) is sufficient to create Barrett's oesophagus. In short, little is known regarding why only some people with GORD develop Barrett's oesophagus and the risk factors for progression from Barrett's oesophagus to oesophageal adenocarcinoma.

Cumulatively, the data extant suggest that gastro‐oesophageal reflux is common but that, even at similar levels of BMI, waist size or reflux symptoms, individual characteristics may influence the risk of oesophagitis, Barrett's oesophagus and oesophageal adenocarcinoma among patients with GORD. Three published studies have evaluated one such individual characteristic, abdominal obesity, in selected populations. A study of 36 veterans with Barrett's oesophagus who had undergone an abdominal CT scan for any reason versus controls suggested that increased abdominal fat was a risk factor for Barrett's oesophagus independent of BMI.18 Another study of patients with Barrett's oesophagus suggested that the risk of histological, flow cytometric and genetic abnormalities rose with increasing abdominal fat but not with increasing BMI,16 implying that the fat distribution pattern may be more influential than the absolute BMI as a risk factor for oesophageal adenocarcinoma. A third community‐based study found that waist circumference, independent of BMI (and not BMI itself), was a risk factor for Barrett's oesophagus.14

Can there be GORD‐independent pathways for oesophageal adenocarcinoma? Though minimal data exist, this seems plausible. BMI and obesity have been associated with several types of cancers that are unrelated to GORD, and the fat distribution pattern may influence general cancer risk to a greater degree than overall adiposity.9,19,20 Even though abdominal obesity may increase the risk of GORD through mechanical mechanisms, via increased intra‐abdominal pressure, this association is unproven and there are minimal population‐based data on the associations between abdominal size and reflux symptoms.12,21 Abdominal obesity (separate from general obesity) has also been found to increase the risk of many cancers, including cancers of the breast and colon,22,23 even though none of these cancers is associated with GORD. Abdominal obesity is also more common among men, making this a potential explanation for the demographic patterns of oesophageal adenocarcinoma. It is thus feasible that BMI and oesophageal adenocarcinoma may be linked through GORD‐independent mechanisms or that these mechanisms may modify the individual response to GORD and GORD‐induced mucosal damage, but do any pathways make biological sense?

There is a body of evidence that suggests that body fat is metabolically active and it may mediate cancer risk, in part, by altering levels of intermediary hormones that modulate inflammation, healing and cell growth.22,24,25,26 Adipose‐associated polypeptides such as leptin, adiponectin, insulin‐like growth factors and ghrelin represent potential GORD‐independent mechanisms for the mediation of cancer risk, or they may mediate the individual response to GORD or even GORD itself. These peptides can modulate mucosal inflammation and healing, have associations with cancer risk for other malignancies, and have plausible biological mechanisms for modifying cancer risk at the cellular level through the modulation of cell proliferation, apoptosis (cell death), angiogenesis (new blood vessel formation) and the cell cycle.27,28,29,30 The adipokines may also vary by gender, possibly by ethnicity and by distributions of body fat (eg, abdominal versus peripheral body fat). These compounds may thus be in the pathway between obesity and oesophageal adenocarcinoma, may partially explain this cancer's unusual gender and ethnic distributions, and represent an interesting area for future inquiry.

In summary, the existing data on oesophageal adenocarcinoma raise as many questions as they do answers. The study by Merry et al. provides additional prospective data supporting an association between BMI and oesophageal adenocarcinoma, but the minimal data on whether this association is mediated solely through acid reflux and the discordance between the prevalence of GORD symptoms and cancer risk by sex and ethnicity leave open the main question: why does the cancer incidence differ so markedly by gender and ethnicity? The answer to this question may direct promising avenues for cancer prevention.

Footnotes

Competing interests: None.

References

1. Pohl H, Welch H G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005. 97142–146.146 [PubMed]
2. Blot W J, McLaughlin J K. The changing epidemiology of esophageal cancer. Semin Oncol 1999. 262–8.8 [PubMed]
3. Corley D A, Kubo A. Influence of site classification on cancer incidence rates: an analysis of gastric cardia carcinomas. J Natl Cancer Inst 2004. 961383–1387.1387 [PubMed]
4. Corley D, Buffler P. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. Int J Epidemiol 2001. 301415–1425.1425 [PubMed]
5. Kubo A, Corley D A. Marked regional variation in adenocarcinomas of the esophagus and the gastric cardia in the United States. Cancer 2002. 952096–2102.2102 [PubMed]
6. Kubo A, Corley D A. Marked multi‐ethnic variation of esophageal and gastric cardia carcinomas within the United States. Am J Gastroenterol 2004. 99582–588.588 [PubMed]
7. Merry A H H, Schouten L J, Goldbohm R A. et al Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardia: a prospective cohort study. Gut 2007. 561503–1511.1511 [PMC free article] [PubMed]
8. Hampel H, Abraham N S, El‐Serag H B. Meta‐analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005. 143199–211.211 [PubMed]
9. Kubo A, Corley D A. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta‐analysis. Cancer Epidemiol Biomarkers Prev 2006. 15872–878.878 [PubMed]
10. Sharma P, McQuaid K, Dent J. et al A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 2004. 127310–330.330 [PubMed]
11. Corley D A, Kubo A. Body mass index and gastroesophageal reflux disease: a systematic review and meta‐analysis. Am J Gastroenterol 2006. 1012619–2628.2628 [PubMed]
12. Corley D A, Kubo A, Zhao W. Abdominal obesity, ethnicity, and gastroesophageal reflux disease. Gut 2006. 56756–762.762 [PMC free article] [PubMed]
13. Westhoff B, Brotze S, Weston A. et al The frequency of Barrett's esophagus in high‐risk patients with chronic GERD. Gastrointest Endosc 2005. 61226–231.231 [PubMed]
14. Corley D A, Kubo A, Levin T R. et al Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology 2007. 13334–41.41 [PubMed]
15. Moe G L, Kristal A R, Levine D S. et al Waist‐to‐hip ratio, weight gain, and dietary and serum selenium are associated with DNA content flow cytometry in Barrett's esophagus. Nutr Cancer 2000. 367–13.13 [PubMed]
16. Vaughan T L, Kristal A R, Blount P L. et al Nonsteroidal anti‐inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2002. 11745–752.752 [PubMed]
17. El‐Serag H B, Petersen N J, Carter J. et al Gastroesophageal reflux among different racial groups in the United States. Gastroenterology 2004. 1261692–1699.1699 [PubMed]
18. El‐Serag H B, Kvapil P, Hacken‐Bitar J. et al Abdominal obesity and the risk of Barrett's esophagus. Am J Gastroenterol 2005. 1002151–2156.2156 [PubMed]
19. Samanic C, Gridley G, Chow W H. et al Obesity and cancer risk among white and black United States veterans. Cancer Causes Control 2004. 1535–43.43 [PubMed]
20. Schapira D V, Kumar N B, Lyman G H. et al Abdominal obesity and breast cancer risk. Ann Intern Med 1990. 112182–186.186 [PubMed]
21. El‐Serag H B, Tran T, Richardson P. et al Anthropometric correlates of intragastric pressure. Scand J Gastroenterol 2006. 41887–891.891 [PubMed]
22. Stoll B A. Upper abdominal obesity, insulin resistance and breast cancer risk. Int J Obes Relat Metab Disord 2002. 26747–753.753 [PubMed]
23. Giacosa A, Franceschi S, La Vecchia C. et al Energy intake, overweight, physical exercise and colorectal cancer risk. Eur J Cancer Prev. 1999;8(Suppl 1)S53–S60.S60
24. Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin‐like growth factor‐I. Proc Nutr Soc 2001. 6091–106.106 [PubMed]
25. Schoen R E, Schragin J, Weissfeld J L. et al Lack of association between adipose tissue distribution and IGF‐1 and IGFBP‐3 in men and women. Cancer Epidemiol Biomarkers Prev 2002. 11581–586.586 [PubMed]
26. Lagergren J. Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut. 2005;54(Suppl 1)i1–i5.i5
27. Bolukbas F F, Kilic H, Bolukbas C. et al Serum leptin concentration and advanced gastrointestinal cancers: a case controlled study. BMC Cancer 2004. 429
28. Bub J D, Miyazaki T, Iwamoto Y. Adiponectin as a growth inhibitor in prostate cancer cells. Biochem Biophys Res Commun 2006. 3401158–1166.1166 [PubMed]
29. Lord G M. Leptin as a proinflammatory cytokine. Contrib Nephrol 2006. 151151–164.164 [PubMed]
30. de Martel C, Haggerty T D, Corley D A. et al Serum ghrelin levels and risk of subsequent adenocarcinoma of the esophagus. Am J Gastroenterol 2007. 1021166–1172.1172 [PubMed]

Articles from Gut are provided here courtesy of BMJ Publishing Group